Kura Oncology, Inc.
Nasdaq KURA · San Diego, CA
Works in Genetic & rare · GI & liver · Hematology · Immunology · Metabolic & endocrine · Neurology · Oncology · Renal & urogenital · Respiratory · Women's health
Kura Oncology, Inc. is a clinical trial sponsor based in San Diego, CA, listed as Nasdaq KURA. It has 6 active clinical trials with 2,611 planned participants, across 10 therapeutic areas. Since 2021 it has completed 5 trials and stopped 4 early.
Trial track record · since 2021
Financials · Nasdaq KURA
Pipeline · 6 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about Kura Oncology, Inc
Kura Oncology, Inc is lead sponsor of 6 active clinical trials on ClinicalTrials.gov, with 2,611 planned participants, in Genetic & rare, GI & liver, Hematology, Immunology and other areas. Since 2021 it has completed 5 trials and stopped 4 early.
Kura Oncology, Inc is based in San Diego, CA and is listed as Nasdaq KURA. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Kura Oncology, Inc; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-14.
Approve Suite is not affiliated with Kura Oncology, Inc..
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.